Orexo AB (publ) (ORXOF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
At close: 09:30AM EDT
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 1.5000 - 1.5000 |
| 52-week range | 1.0400 - 1.9500 |
| Volume | |
| Avg. volume | 47 |
| Market cap | 53.208M |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3400 |
| Earnings date | 08 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireReport from Orexo AB's annual general meeting, 26 April 2024
Election of the board of directors and auditor
PR NewswireOrexo extends patent protection for its nasal epinephrine powder product OX640 in the US
Orexo AB (publ.), (STO: ORX) (OTCQX: ORXOY) today announces that the United States Patent and Trademark Office (USPTO) has granted another US patent specifically related to OX640, Orexo's nasal epinephrine powder product based on the AmorphOX® drug delivery platform.
PR NewswireOrexo announces that the condition for early redemption of its existing bonds has been fulfilled
On March 13, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO:ORX) (OTCQX:ORXOY) announced that the Company intends to redeem early the Company's existing senior unsecured bonds with maturity in February 2025 (ISIN SE0015193958) (the "Existing Bonds").
© 2024 Yahoo. All rights reserved.